Accolade Inc is a technology-driven healthcare company that offers personalized health and benefits solutions
The company leverages data analytics and artificial intelligence to provide individuals and employers with tailored guidance in navigating complex healthcare systems. By pairing users with dedicated health assistants, Accolade aims to simplify healthcare decisions, enhance user experience, and improve health outcomes while helping organizations manage costs associated with employee health benefits. Through its innovative platform, the company optimizes access to care, navigates insurance options, and supports overall wellness initiatives.
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.
BALA CYNWYD, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Transcarent to acquire Accolade Inc. for $7.03 per share, combining AI-driven care solutions with personalized healthcare expertise. Deal closes Q2 2025.
Ademi LLP is investigating Accolade (NASDAQACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders.
Transcarent, the One Place for Health and Care, and Accolade (NASDAQACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, will enhance Transcarent's mission to make it easy for people to access high-quality, affordable health and care. The combined platform will deliver a more personalized and engaging Member experience.
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal second quarter ended August 31, 2024.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD.
